256 related articles for article (PubMed ID: 3252045)
1. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans.
Abernethy DR; Egan JM; Dickinson TH; Carrum G
J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045
[TBL] [Abstract][Full Text] [Related]
2. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state.
Teunissen MW; De Leede LG; Boeijinga JK; Breimer DD
J Pharmacol Exp Ther; 1985 Jun; 233(3):770-5. PubMed ID: 4009489
[TBL] [Abstract][Full Text] [Related]
3. The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione.
Ohashi K; Sakamoto K; Sudo T; Tateishi T; Harada K; Fujimura A; Ebihara A; Tanaka E
J Clin Pharmacol; 1991 Dec; 31(12):1132-6. PubMed ID: 1761736
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene.
Groen K; Breimer DD; van Bezooijen CF
Drug Metab Dispos; 1992; 20(4):502-6. PubMed ID: 1356725
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of warfarin metabolism by diltiazem in humans.
Abernethy DR; Kaminsky LS; Dickinson TH
J Pharmacol Exp Ther; 1991 Apr; 257(1):411-5. PubMed ID: 2020000
[TBL] [Abstract][Full Text] [Related]
6. The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.
Sakai H; Kobayashi S; Hamada K; Iida S; Akita H; Tanaka E; Uchida E; Yasuhara H
Br J Clin Pharmacol; 1991 Mar; 31(3):353-5. PubMed ID: 2054276
[TBL] [Abstract][Full Text] [Related]
7. Effect of calcium channel blockers on theophylline disposition.
Sirmans SM; Pieper JA; Lalonde RL; Smith DG; Self TH
Clin Pharmacol Ther; 1988 Jul; 44(1):29-34. PubMed ID: 3391002
[TBL] [Abstract][Full Text] [Related]
8. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M
Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486
[TBL] [Abstract][Full Text] [Related]
9. The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine.
Bottorff MB; Lalonde RL; Kazierad DJ; Hoon TJ; Tsiu SJ; Mirvis DM
Pharmacotherapy; 1989; 9(5):315-21. PubMed ID: 2510135
[TBL] [Abstract][Full Text] [Related]
10. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
Bach D; Blevins R; Kerner N; Rubenfire M; Edwards DJ
Br J Clin Pharmacol; 1986 Jun; 21(6):655-9. PubMed ID: 3741715
[TBL] [Abstract][Full Text] [Related]
11. Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine.
Carrum G; Egan JM; Abernethy DR
Clin Pharmacol Ther; 1986 Aug; 40(2):140-3. PubMed ID: 3731677
[TBL] [Abstract][Full Text] [Related]
12. Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats.
Teunissen MW; Van Graft M; Vermeulen NP; Breimer DD
Xenobiotica; 1983 Aug; 13(8):497-502. PubMed ID: 6649682
[TBL] [Abstract][Full Text] [Related]
13. Effect of nifedipine on antipyrine and theophylline disposition.
Adebayo GI; Mabadeje AF
Biopharm Drug Dispos; 1990 Mar; 11(2):157-64. PubMed ID: 2183884
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat.
Adedoyin A; Aarons L; Houston JB
Drug Metab Dispos; 1987; 15(1):127-32. PubMed ID: 2881749
[TBL] [Abstract][Full Text] [Related]
15. The influence of dietary restriction on the metabolism of theophylline and antipyrine in the ageing female BN/BiRij rat.
Groen K; Breimer DD; Brouwer A; Schijff G; Jansen EJ; van Bezooijen CF
J Pharmacol Exp Ther; 1995 Jul; 274(1):143-7. PubMed ID: 7616391
[TBL] [Abstract][Full Text] [Related]
16. Incidence of a subclinical fascioliasis on antipyrine clearance and metabolite excretion in sheep.
Tufenkji AE; Alvinerie M; Pineau T; Boulard C; Galtier P
Xenobiotica; 1988 Apr; 18(4):357-64. PubMed ID: 3400265
[TBL] [Abstract][Full Text] [Related]
17. Effect of fusidic acid on the hepatic cytochrome P450 enzyme system.
Reimann G; Barthel B; Rockstroh JK; Spatz D; Brockmeyer NH
Int J Clin Pharmacol Ther; 1999 Nov; 37(11):562-6. PubMed ID: 10584978
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the effects of labetalol, verapamil and diltiazem on antipyrine and indocyanine green clearances.
Rocci ML; Vlasses PH; Lener ME; Fruncillo RA; Sirgo MA
J Clin Pharmacol; 1989 Oct; 29(10):891-5. PubMed ID: 2592580
[TBL] [Abstract][Full Text] [Related]
19. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD
Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432
[TBL] [Abstract][Full Text] [Related]
20. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.
Bauer LA; Stenwall M; Horn JR; Davis R; Opheim K; Greene L
Clin Pharmacol Ther; 1986 Aug; 40(2):239-42. PubMed ID: 3731687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
